TBGNF - ThromboGenics NV

Other OTC - Other OTC Delayed Price. Currency in USD

ThromboGenics NV

Gaston Geenslaan 1
Leuven 3001
32 1 675 13 10

Full Time Employees80

Key Executives

Dr. Patrik De Haes ViBio, BVBA, M.D.Chief Exec. Officer and Exec. Director586.48kN/AN/A
Mr. Paul G. HowesExec. Director and Exec. Chairman of Thrombogenics Inc23.27kN/A63
Mr. Dominique VanfleterenChief Financial OfficerN/AN/AN/A
Mr. Wouter PiepersGlobal Head of Corp. Communications & Investor RelationsN/AN/AN/A
Mr. Claude SanderChief Legal Officer, Corp. Compliance Officer and Sec.N/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


ThromboGenics NV, an integrated biopharmaceutical company, develops and commercializes medicines that address unmet clinical needs in ophthalmology in Belgium and internationally. The company’s lead product is JETREA used for the treatment of symptomatic vitreomacular adhesion and vitreomacular traction. It has research and development agreements with BioInvent International AB to develop Anti-PlGF, a product candidate to treat Medulloblastoma, a pediatric malignant brain tumor; Eleven Biotherapeutics and Bicycle Therapeutics to develop and commercialize products for the treatment of eye diseases with diabetics; and Chilltern International, Inc. and Outcome Sciences, Inc., as well as Parexel to provide clinical research services for the development of JETREA. The company was founded in 1991 and is headquartered in Leuven, Belgium.

Corporate Governance

ThromboGenics NV’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.